Advanced Science |PCGP Nanoshield Restores Endothelial Mitochondrial Homeostasis Against In‑Stent Restenosis
Multifunctional PCGP bio-interface achieves antithrombosis, immunomodulation and sustained vascular repair HUSTON, TX,
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Multifunctional PCGP bio-interface achieves antithrombosis, immunomodulation and sustained vascular repair
HUSTON, TX, UNITED STATES, November 16, 2026 /EINPresswire.com/ — Drug-eluting stents have revolutionized interventional cardiovascular therapy, yet in-stent restenosis and late stent thrombosis remain persistent clinical challenges largely caused by insufficient re-endothelialization. Published in Advanced Science, this study develops a multifunctional PCGP nanoshield coating for vascular stents. Rather than merely suppressing cellular proliferation, the bioactive coating rescues endothelial mitochondrial homeostasis to drive genuine vascular regeneration. RAW 264.7 macrophages sourced from Cloud-Clone were applied to characterize the material-driven immunomodulatory effects, delivering key cellular evidence supporting this new stent-coating strategy.
Mechanical injury during stent deployment strips off native endothelial layers, triggering platelet activation, inflammatory cell infiltration and reactive oxygen species bursts. Damaged residual endothelial cells fail to rebuild an intact endothelial barrier, which enables excessive smooth-muscle-cell proliferation and leads to luminal renarrowing. Conventional rapamycin-eluting stents curb neointimal hyperplasia by broad proliferation inhibition, but this approach also hinders endothelial regrowth and elevates long-term thrombotic risk. Mitochondria serve as central signalling hubs governing endothelial redox balance, nitric-oxide production and cell survival. Although mitochondrial dysfunction is implicated in multiple cardiovascular disorders, its causal contribution to stent-associated endothelial damage had not been systematically explored.
Integrating single-cell transcriptomics, ultrastructural observation, cellular assays, rabbit stent implantation and rodent subcutaneous models, researchers identified disrupted endothelial mitochondrial homeostasis as a core pathological driver of impaired stent-site repair. The team synthesized PCGP nanoparticles (Mn ≈ 1155 Da) via one-pot thermal polycondensation of citrate, polyethylene glycol and procyanidin. Each component performs distinct complementary roles: citrate replenishes tricarboxylic-acid-cycle intermediates to restore mitochondrial respiration while exerting anticoagulant calcium-chelating activity; polyethylene glycol constructs a hydration layer to resist non-specific protein and platelet adhesion; procyanidin preserves mitochondrial membrane potential and mediates anti-oxidant and immunomodulatory effects.
Using a mussel-inspired polydopamine primer combined with EDC/NHS covalent anchoring, PCGP was assembled onto stent surfaces, forming an ~88 nm-thick nanoscale interface with 3.1 nm surface roughness. The coating maintains structural integrity even after balloon expansion. It achieves multi-level antithrombotic protection through calcium chelation, PEG-mediated anti-fouling, and electrostatic repulsion towards fibrinogen. Distinct from conventional mono-functional stent coatings, this PCGP nanoshield integrates mitochondrial protection, anticoagulation and immunomodulation within one bio-interface.
In vitro oxidative-stress experiments demonstrated robust endothelial protection by PCGP. The coating lowered intracellular and mitochondrial ROS, stabilized mitochondrial membrane potential, preserved cristae architecture, and rescued tricarboxylic-acid-cycle and oxidative-phosphorylation gene expression. It reduced endothelial apoptosis, restored migration and tube-forming capacity, and suppressed pro-inflammatory molecule secretion. Experiments with rotenone-induced pure mitochondrial injury further confirmed that mitochondrial dysfunction directly compromises endothelial regeneration, and that PCGP can reverse such defects. RNA-seq and western-blot results verified re-activation of the PI3K/AKT/eNOS-NO signalling axis as the key downstream repair pathway.
In rabbit aortic stent models, PCGP treatment yielded sustained suppression of neointimal hyperplasia at both 3-week and 3-month time points. By comparison, rapamycin-eluting stents showed satisfactory short-term outcomes yet obvious late rebound of neointimal proliferation, oxidative stress and inflammation. Stents coated with PCGP supported complete, well-aligned endothelial coverage at 3 weeks and near-native-like endothelium by 3 months, whereas re-endothelialization remained incomplete in the rapamycin group. PCGP maintained the contractile phenotype of vascular smooth muscle cells and exhibited favourable biosafety in major organs. Thrombosis assays confirmed significantly reduced platelet and erythrocyte adhesion, alongside preserved luminal patency in arteriovenous shunt tests.
To assess immunomodulatory capacity, RAW 264.7 mouse monocyte-macrophage cells obtained from Cloud-Clone were seeded onto material surfaces. Macrophages adopted a resting rounded morphology on PCGP coatings. Upon LPS stimulation, PCGP shifted macrophage polarization toward the reparative M2 phenotype, accompanied by down-regulated M1-associated markers and pro-inflammatory cytokines TNF-α and IL-6. Subcutaneous rodent implantation further validated thinner fibrous capsules and alleviated local inflammatory responses with PCGP materials.
This study proposes a mechanism-driven biomaterial development workflow: identifying mitochondrial-related pathological defects via multi-omics and ultrastructural analysis, designing multi-component materials to target the root cause, and performing closed-loop validation through mechanistic investigations and in-vivo models. Several limitations remain. Hydrogen-peroxide-based oxidative-stress models cannot fully recapitulate complex haemodynamic and multicellular conditions after stent implantation. Human umbilical vein endothelial cells do not perfectly recapitulate arterial endothelial physiology. Future investigations using primary arterial endothelial cells, advanced flow platforms and metabolomic profiling will deepen translational understanding.
Moving beyond the traditional paradigm of inhibiting pathological proliferation, the PCGP nanoshield demonstrates that restoring endothelial mitochondrial homeostasis represents a promising strategy for next-generation vascular implants. Cloud-Clone RAW 264.7 macrophages provided reproducible cellular readouts for material immunomodulation, supporting the multi-faceted pre-clinical evidence chain. This work offers actionable design principles for developing regenerative bio-interfaces that actively rebuild vascular homeostasis for interventional cardiovascular medicine.
SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery

